Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $39.00.

COLL has been the subject of several recent analyst reports. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 29th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Piper Sandler reiterated an “overweight” rating and issued a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Truist Financial increased their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 23,560 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $32.28, for a total transaction of $760,516.80. Following the sale, the executive vice president now directly owns 111,322 shares in the company, valued at approximately $3,593,474.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 3.69% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SummerHaven Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical by 1.1% in the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after acquiring an additional 368 shares during the period. Illinois Municipal Retirement Fund raised its holdings in Collegium Pharmaceutical by 2.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock worth $612,000 after purchasing an additional 411 shares during the last quarter. West Tower Group LLC lifted its position in shares of Collegium Pharmaceutical by 101.8% in the 4th quarter. West Tower Group LLC now owns 892 shares of the specialty pharmaceutical company’s stock worth $27,000 after purchasing an additional 450 shares during the period. Maverick Capital Ltd. boosted its stake in shares of Collegium Pharmaceutical by 5.2% in the 1st quarter. Maverick Capital Ltd. now owns 11,296 shares of the specialty pharmaceutical company’s stock valued at $271,000 after purchasing an additional 555 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Collegium Pharmaceutical by 0.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock valued at $1,718,000 after purchasing an additional 585 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

COLL opened at $35.71 on Friday. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. Collegium Pharmaceutical has a 52-week low of $20.83 and a 52-week high of $40.95. The firm has a market cap of $1.17 billion, a P/E ratio of 30.26 and a beta of 1.03. The business’s fifty day moving average is $36.69 and its 200-day moving average is $30.39.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. The firm had revenue of $149.75 million for the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. Sell-side analysts expect that Collegium Pharmaceutical will post 5.63 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.